The Effect of @entity1872 in Primary XXXX : An Analysis of a Large Cohort From a Single Center in China.

@entity1 @entity3039 @entity1872
AIM: This study assessed the long-term benefits and side effects of low-to-medium dose of @entity1872 therapy in primary @entity3039 ( @entity3039 ). METHODS: The retrospective analysis included 319 @entity1 with @entity3039 who accepted @entity1872 therapy. @entity1 accepted @entity1872 alone or in combination with glucocorticoids. Clinical outcome and tolerance were assessed in all @entity1 . RESULTS: Among @entity1 with persistent or chronic @entity3039 , the overall response rate of @entity1872 therapy was 65.0%. Sixty-five (63.1%) of the 103 @entity1 reached remission with @entity1872 alone, and 93 (48.7%) of the 191 @entity1 who accepted combination therapies acquired remission and discontinued glucocorticoids successfully. Age and previous treatments were 2 risk factors for response rate. In newly diagnosed @entity1 with @entity3039 , the response rate and median response time did not differ significantly with or without @entity1872 . However, the relapse rate was significantly lower in @entity1 administered @entity1872 combined with glucocorticoids than those accepted glucocorticoids alone. Totally, 21.1% of the @entity1 experienced mild or moderate side effects, and 1.2% of the @entity1 discontinued treatment due to intolerable side effects. CONCLUSION: Low-to-medium dosage of @entity1872 is better tolerated and effective in @entity1 with @entity3039 , even in those refractory to other treatments. Combination of @entity1872 and glucocorticoids for initial treatment may decrease relapse rates to achieve well-tolerated long-term remission.
